Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Catalyst Pharmaceuticals (Nasdaq: CPRX), a commercial-stage biopharmaceutical company specializing in rare and difficult-to-treat diseases, has announced its participation in four upcoming investor conferences in September 2025.
The company's management team, led by CEO Richard J. Daly, will present at the Wells Fargo Healthcare Conference (Sept. 3), Cantor Global Healthcare Conference (Sept. 4), H.C. Wainwright Global Investment Conference (Sept. 8), and Baird Global Conference (Sept. 9). All presentations will be available via webcast on the company's website with replays accessible for 30 days.
Catalyst Pharmaceuticals (Nasdaq: CPRX), azienda biofarmaceutica in fase commerciale specializzata in malattie rare e difficili da trattare, ha comunicato la sua partecipazione a quattro conferenze per investitori previste per settembre 2025.
Il team di gestione, guidato dall'Amministratore Delegato Richard J. Daly, terrà presentazioni al Wells Fargo Healthcare Conference (3 settembre), al Cantor Global Healthcare Conference (4 settembre), all'H.C. Wainwright Global Investment Conference (8 settembre) e al Baird Global Conference (9 settembre). Tutti gli interventi saranno trasmessi in webcast sul sito dell'azienda e rimarranno disponibili in replay per 30 giorni.
Catalyst Pharmaceuticals (Nasdaq: CPRX), una compañía biofarmacéutica en fase comercial especializada en enfermedades raras y de difícil tratamiento, ha anunciado su participación en cuatro conferencias para inversores programadas para septiembre de 2025.
El equipo directivo, encabezado por el CEO Richard J. Daly, ofrecerá presentaciones en el Wells Fargo Healthcare Conference (3 de septiembre), el Cantor Global Healthcare Conference (4 de septiembre), el H.C. Wainwright Global Investment Conference (8 de septiembre) y el Baird Global Conference (9 de septiembre). Todas las presentaciones se emitirán por webcast en la web de la compañía y estarán disponibles en replay durante 30 días.
Catalyst Pharmaceuticals (Nasdaq: CPRX), 희귀 질환 및 치료가 어려운 질환을 전문으로 하는 상업 단계의 바이오제약 회사가 2025년 9월에 열리는 4개의 투자자 컨퍼런스에 참여한다고 발표했습니다.
CEO 리처드 J. 데일리(Richard J. Daly)가 이끄는 경영진은 Wells Fargo Healthcare Conference(9월 3일), Cantor Global Healthcare Conference(9월 4일), H.C. Wainwright Global Investment Conference(9월 8일), Baird Global Conference(9월 9일)에서 발표할 예정입니다. 모든 발표는 회사 웹사이트를 통해 웹캐스트로 제공되며 재생은 30일간 이용할 수 있습니다.
Catalyst Pharmaceuticals (Nasdaq: CPRX), une société biopharmaceutique en phase commerciale spécialisée dans les maladies rares et difficiles à traiter, a annoncé sa participation à quatre conférences investisseurs en septembre 2025.
L'équipe de direction, dirigée par le CEO Richard J. Daly, présentera lors du Wells Fargo Healthcare Conference (3 septembre), du Cantor Global Healthcare Conference (4 septembre), du H.C. Wainwright Global Investment Conference (8 septembre) et du Baird Global Conference (9 septembre). Toutes les présentations seront diffusées en webcast sur le site de la société et resteront disponibles en replay pendant 30 jours.
Catalyst Pharmaceuticals (Nasdaq: CPRX), ein kommerziell tätiges Biopharmaunternehmen, das auf seltene und schwer zu behandelnde Erkrankungen spezialisiert ist, hat seine Teilnahme an vier Investorenkonferenzen im September 2025 angekündigt.
Das Managementteam unter der Leitung von CEO Richard J. Daly wird Präsentationen auf der Wells Fargo Healthcare Conference (3. September), der Cantor Global Healthcare Conference (4. September), der H.C. Wainwright Global Investment Conference (8. September) und der Baird Global Conference (9. September) halten. Alle Präsentationen werden per Webcast auf der Unternehmenswebsite verfügbar sein und können 30 Tage lang als Wiedergabe abgerufen werden.
- None.
- None.
CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below.
2025 Wells Fargo Healthcare Conference
Date: Wednesday, September 3, 2025
Presentation: 2:15 PM ET
Webcast Link
2025 Cantor Global Healthcare Conference
Date: Thursday, September 4, 2025
Presentation: 3:20 PM ET
Webcast Link
H.C. Wainwright 27th Annual Global Investment Conference
Date: Monday, September 8, 2025
Presentation: 9:00am ET
Webcast Link
Baird Global Conference
Date: Tuesday, September 9, 2025
Presentation: 12:50pm ET
Webcast Link
The webcasts will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com
FAQ
When is Catalyst Pharmaceuticals (CPRX) presenting at the Wells Fargo Healthcare Conference 2025?
Who will represent Catalyst Pharmaceuticals at the upcoming investor conferences?
How can investors access Catalyst Pharmaceuticals' conference presentations?
What is the schedule for Catalyst Pharmaceuticals' September 2025 conference presentations?
